课题基金 / 基金详情

Increase in antithrombotic function vascular endothelium antithrombin-III

Increase in antithrombotic function vascular endothelium antithrombin-III
抗血栓功能增加血管内皮抗凝血酶-III
批准号:
11838017
负责人:
ISHII Hidemi
金额:
$2.24万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2001

项目摘要

项目成果

ISHII Hidemi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Normal vascular endothelial cells preferentially produce antithrombotic factors such as prostaglandin 12 and thrombomodulin than preduction of prothrombotic factors such as tissue factor, so that the cells are preventing thrombus formation. However, if the cells are stimulated by various agonists in the blood, the cells change balance to reduce production of antithrombomotic factors and increase production of prothrombotic factor, so that the blood was turned to form thrombus. Antithrombin-III(AF-III), which is a physiological inhibitor for thrombin, stimulates endothelial cells and induces production of prostaglandin I2. The present studies were undertaken to evaluate whether AT-III can promote various antithrombotic functions in endothelial cells other than the induced production of prostaglandin I2.1. When cultured vascular endothelial cells were exposed to TNFα, the cells induce tissue factor (TF) expression on the membrane surface of the cells through up-regulation of TF transcription. Pretreatment of the cells with At-III prevented TNFα-induced TF expression through depression of TF gene transcription.2. Expression of ELAM-1, which is a adhesion molecule for lenkocytes, was induced by exposure of endothelial cells to bleomycin, a anticancer drug, on the cell surface through up-regulation of ELAM-1 transcription. AT-III pretreatment did not prevent the bleomycin-induced ELAM-1 expression.3. Oxidized phospholipid in oxidized LDL reduced expression of RARs, RXRα and Sp1 proteins in endothelial cells. These reduced proteins induced thrombomodulin(TM) expression on the surface of the cells through suppression of transcription of TM gene. AT-III pretreatment did not prevent oxidized LDL-induced down-regulation of TM. These results suggested that AT-III can act as antithomotic agent through inhibition of thrombin and induction of prostaglandin I2 producion, but not the bleomycin-induced ELAM-1 expression and the oxidized LDL-induced TM down-regulation.
期刊论文(41)
专著(0)
科研奖励(0)
会议论文
濱島肇: "DNA塩基配列解析"血液・腫瘍科. 40(3). 440-445 (2000)
Hajime Hamashima:“DNA 序列分析”,血液学和肿瘤学 40(3) (2000)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
後藤佐多良: "病態生化学"朝倉書店. 172 (1999)
Satara Goto:《病理生物化学》朝仓书店 172 (1999)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
中島憲一郎: "衛生薬学"廣川書店. 429 (1999)
中岛健一郎:《卫生药房》广川书店429(1999)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
石井秀美: "衛生薬学"広川書店. 75/429 (2001)
石井秀美:《卫生药房》广川书店 75/429 (2001)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
34
    Analysis of function and regulation mechanism of expression of thrombomodulin, a regulating factor of blood coagulation, on surface of endothelial cells
    • 批准号:
      03833027
    • 项目类别:
      Grant-in-Aid for General Scientific Research (C)
    • 资助金额:
      $0.83万
    • 财政年份:
      1991
    • 负责人:
      ISHII Hidemi
    • 依托单位:
    海外基金